Palmer D, Schürch S, Belik J
Respiratory Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
J Appl Physiol (1985). 2000 Sep;89(3):884-90. doi: 10.1152/jappl.2000.89.3.884.
The objective of this study was to evaluate the in vitro effect of budesonide and salbutamol on the surfactant biophysical properties. The surface-tension properties of two bovine lipid extracts [bovine lipid extract surfactant (BLES) and Survanta] and a rat lung lavage natural surfactant were evaluated in vitro by the captive bubble surfactometer. Measurements were obtained before and after the addition of a low and high concentration of budesonide and salbutamol. Whereas salbutamol had no significant effect, budesonide markedly reduced the surface-tension-lowering properties of all surfactant preparations. Surfactant adsorption (decrease in surface tension vs. time) was significantly reduced (P < 0.01) at a high budesonide concentration with BLES, both concentrations with Survanta, and a low concentration with natural surfactant. At both concentrations, budesonide reduced (P < 0.01) Survanta film stability (minimal surface vs. time at minimum bubble volume), whereas no changes were seen with BLES. The minimal surface tension obtained for all surfactant preparations was significantly higher (P < 0.01), and the percentage of film area compression required to reach minimum surface tension was significantly lower after the addition of budesonide. In conclusion, budesonide, at concentrations used therapeutically, adversely affects the surface-tension-lowering properties of surfactant. We speculate that it may have the same adverse effect on the human surfactant.
本研究的目的是评估布地奈德和沙丁胺醇对表面活性剂生物物理特性的体外作用。通过俘获气泡表面张力仪在体外评估了两种牛脂质提取物[牛脂质提取物表面活性剂（BLES）和固尔苏]以及大鼠肺灌洗天然表面活性剂的表面张力特性。在添加低浓度和高浓度的布地奈德和沙丁胺醇之前和之后进行测量。沙丁胺醇没有显著影响，而布地奈德显著降低了所有表面活性剂制剂的表面张力降低特性。在高浓度布地奈德作用下，BLES的表面活性剂吸附（表面张力降低与时间的关系）显著降低（P<0.01），固尔苏在两种浓度下以及天然表面活性剂在低浓度下均如此。在两种浓度下，布地奈德均降低了（P<0.01）固尔苏的膜稳定性（最小表面张力与最小气泡体积下的时间关系），而BLES未见变化。添加布地奈德后，所有表面活性剂制剂获得的最小表面张力显著更高（P<0.01），达到最小表面张力所需的膜面积压缩百分比显著更低。总之，治疗浓度的布地奈德会对表面活性剂的表面张力降低特性产生不利影响。我们推测它可能对人表面活性剂有同样的不利影响。
